While we demonstrate that dipyridamole alone can decrease tumour growth with no obvious side effects, and that the effect seen is specific to EDI3, the identification of a specific EDI3 inhibitor will be a critical next step towards understanding the relevance of EDI3 as a therapeutic target in HER2-targeted therapy resistant breast cancer. Here, ERBB2 is linked to breast carcinoma.